My ePortfolio Register   

Mechanisms of resistance in triple negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.03.17
Views: 839

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Loi speaks with ecancer at 2017 St. Gallen International Breast Cancer Conference about the oncogenic pathways upregulated in triple negative breast cancer, which can be highly resistant to chemotherapy.

She highlights how genome sequencing has unveiled a patchwork of heterogeneity in tumours, with gene replication and a varied sea of clonotypes which leave targeted or immune therapies unable to deliver significant damage.

Prof Loi hopes that further understanding of these mechanisms will aid in developing combinations of therapies for the disease.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence